Ligand id: 5608

Name: istradefylline

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 6
Hydrogen bond donors 0
Rotatable bonds 6
Topological polar surface area 76.9
Molecular weight 384.18
XLogP 2.33
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Approved in Japan only, for the treatment of Parkinson's disease.
Mechanism Of Action and Pharmacodynamic Effects
Istradefylline is an adenosine A2A receptor antagonist [1-2]. It is reported that in animal models istradefylline is able to reverse the motor impairments induced by dopamine depletion or antagonism, however this does not appear to translate to human Parkinson's patients with any significant improvement over placebo or levodopa in Phase 3 trial.